Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ismaili N et al. - The most common staging system used is the two-stage system (limited-extensive). Because of the rarity of the disease, the management is extrapolated from that of SCLC. Limited-stage disease should be treated with etoposide-cisplatin chemotherapy in combination either with radiotherapy, or surgery or both. Extensive-stage disease should be managed by combined chemotherapy.

Related Articles

Incidence analyses of bladder cancer in the Nile delta region of Egypt
Cancer Epidemiology, 10/20/09    Relevance Score: 84%

Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09    Relevance Score: 83%

192R Allele of Paraoxanase 1 (PON1) Gene as a New Marker for Susceptibility to Bladder Cancer
Anticancer Research, 11/10/09    Relevance Score: 83%

Evidence-based Principles of Bladder Cancer and Diet
Urology, 10/21/09    Relevance Score: 83%

Biomarkers in bladder cancer
BJU International, 10/01/09    Relevance Score: 83%

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address